Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (6594)	1/28/2001 12:04:19 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Wolf, are you aware of www.imshealth.com? Anyone know anyone who may have a subscription to this service? IMS HEALTH is the world's premier supplier of market research, business analysis, forecasting and sales management services to the global pharmaceutical industry. With offices in more than 60 countries and information services in over 80 countries, IMS HEALTH is well acquainted with the global nature of healthcare and the broad, but detailed, view needed to understand the industry. As a neutral and independent observer, IMS is expertly positioned to supply data and business solutions to organisations throughout the healthcare environment. Over the past four decades, IMS HEALTH has developed the most direct channels for information procurement in all its markets, allowing the tracking of product movement, buying trends, physicians' prescription patterns, doctor / patient interactions and disease treatment patterns. As a unit of IMS HEALTH, Global Services provide a focus on the international strategic processes of the pharmaceutical company headquarters, consolidating all the local IMS data sources with other added value services.

To: Montana Wildhack who wrote (6594)	1/28/2001 7:53:09 AM
From: Tom Gordon	Read Replies (1) \| Respond to of 14101

Wolf, When I alluded to the reference of "uncertain variables", I was indirectly referring to the "risk to reward" nature of this beast. You can see the dominos falling , and as you mention in your posts, 1)UK approval 2)Provalis and UK distribution inception 3)Acqua financing deal 4) EU deal? 5)EU distributor ? 6)FDA or HC 7)NA distributor 8)Nasdaq All of this is very possible within that 13 month time frame. Forgot about the positive earnings and revenue out of the UK by mid-year. Regards Tom G.